Carlyle Group (NASDAQ: CG) is considering acquiring Baxter International's (NYSE: BAX) kidney care spinoff, Vantive, in a deal valued at more than $4 billion, including debt. The news was first reported by Wall Street Journal, citing people familiar with the matter.
Per the source, the companies started exclusive negotiations in late June and an agreement could be announced as soon as this week. However, there is a chance that the discussions will fail or another bidder may emerge.
More than a year after announcing plans to separate the unit due to supply-chain issues and waning demand for dialysis operations, Baxter said in March that it has been in talks with selected ...